Company Information & Drug Savings for Aveo Pharmaceuticals Medications

AVEO Oncology is a biopharmaceutical company focused on developing targeted cancer therapies. The company created FOTIVDA (tivozanib), an oral VEGF receptor tyrosine kinase inhibitor approved for relapsed or refractory advanced renal cell carcinoma (kidney cancer). AVEO’s precision oncology approach targets tumor angiogenesis and specific molecular pathways in cancer progression.